A Case of Rapid Improvement of Symptoms in Severe Guillain-Barr$\acute{e}$ Syndrome after Additional Use of Intravenous Immunoglobulin

추가적인 면역글로불린 투여에 빠른 증상 호전을 보인 심한 길랭-바레증후군 1예

Kim, Doo Hyun (Department of Neurology, Yeungnam University College of Medicine) ;
Park, Min Su (Department of Neurology, Yeungnam University College of Medicine)

Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2010:CD002063.
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain- Barre syndrome. J Clin Immunol 2010;30:S74-78.
Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I. Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-BarrE syndrome. Lancet 1997;350:1747.
Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009;66:597-603.
Merkies IS, Schmitz PI, van der Meche FG, Samijn JP, van Doorn PA. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 2002;72:596-601.
Vedeler C, Wik E, Nyland H. The long-term prognosis of Guillain-Barre syndrome. Evaluation of prognostic factors including plasma exchange. Acta Neurologica Scand 1997;95: 298-302.
Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, Yokochi M, et al. Factors influencing outcome in Guillain-Barre Syndrome: comparison of plasma adsorption against other treatments. Clinical Neurol Neurosurg 2005;107:491-496.